title: Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival.
abstract: BACKGROUND
  MicroRNAs (miRNAs) are noncoding RNAs that regulate multiple cellular processes during cancer progression. MiR-630 has recently been identified to be involved in tumorigenesis of several cancers such as lung cancer and gastric cancer. However, the regulation of miR-630 in clear cell renal cell carcinoma (ccRCC) has not yet been reported before.
  
  
  METHODS
  Expression of miR-630 was evaluated by quantitative real-time PCR in tumour and their normal matched tissues in n = 92 ccRCC patients, and its association with overall survival of patients was analyzed by statistical analysis.
  
  
  RESULTS
  The expression level of miR-630 was significantly higher in renal cancer in comparison to normal matched tissue (P < 0.05). It is also proved that miR-630 expression was to be associated with renal cancer histologic grade, lymphnode metastasis, distant metastasis (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that high miR-630 expression was associated with poor prognosis in ccRCC patients. miR-630 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis.
  
  
  CONCLUSIONS
  The study proves for the first time that miR-630 is upregulated in a majority of ccRCC patients. It also shows that miR-630 expression is an independent prognostic factor for patients with renal cancer, which might be a potential valuable biomarker for ccRCC.
authors.affiliation: Department of Surgery, The Fourth Hospital of Hebei Medical University Shijiazhuang, 050011, Hebei, China ; Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China.
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Zhao
authors.affiliation: Department of Neurology, Handan Central Hospital Handan, 056001, Hebei, China.
authors.forename: Peng-Jie
authors.initials: PJ
authors.lastname: Chen
authors.affiliation: Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China.
authors.forename: Rui-Qin
authors.initials: RQ
authors.lastname: Duan
authors.affiliation: Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China.
authors.forename: Ke-Ji
authors.initials: KJ
authors.lastname: Li
authors.affiliation: Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China.
authors.forename: Yu-Zhong
authors.initials: YZ
authors.lastname: Wang
authors.affiliation: Department of Surgery, The Fourth Hospital of Hebei Medical University Shijiazhuang, 050011, Hebei, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis*; D008875:Middle Aged; D016016:Proportional Hazards Models; D060888:Real-Time Polymerase Chain Reaction; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C548399:MIRN630 microRNA, human; D035683:MicroRNAs
keywords: clear cell renal cell carcinoma; miR-630; prognosis; quantitative real-time PCR